Continue reading this on our app for a better experience

Open in App
Floating Button
Home News Company in the news

Pfizer drug helped cancer patients regain weight: study

Bloomberg
Bloomberg • 3 min read
Pfizer drug helped cancer patients regain weight: study
Pfizer is discussing development plans with regulatory agencies and aims to begin registration-enabling studies in 2025. Photo: Bloomberg
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Pfizer’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.

In cancer patients, a syndrome called cachexia causes changes in metabolism and appetite. It can lead to the loss of critical skeletal muscle and fat that weakens the body and, in some cases, can make cancer treatments less effective. Studies suggest that as much as 30% of all cancer deaths are caused by cachexia and about 80% of patients with advanced stage cancers are affected by the condition. There are currently no drugs approved to treat it.

Pfizer’s drug, called ponsegromab, is a monoclonal antibody that blocks GDF-15, a protein expressed when the body is under extreme stress. High GDF-15 levels in cancer patients are thought to be associated with loss of appetite and nausea, which led Pfizer’s scientists to hypothesize that blocking the protein’s expression could prevent the onset of cachexia. 

The drug was discovered in-house at Pfizer, which has been looking to cancer drugs to drive its next growth chapter. Last year, the company bought cancer drugmaker Seagen for US$43 billion ($55.84 billion), and investors have been hungry for positive news as its Covid vaccine sales continue to dwindle.

Pfizer enrolled 187 patients with cancer and high levels of GDF-15 in a Phase 2 study that tested ponsegromab’s effect on body weight compared with a placebo. Patients in the trial had non-small cell lung cancer, pancreatic cancer or colorectal cancer, and about 75% of them had progressed to stage 4. 

At the highest 400 milligram dose, patients regained about 5.6% of their body weight in 12 weeks, according to results published Saturday in the New England Journal of Medicine. Those patients also saw improvements in appetite, physical activity levels and skeletal muscle, according to the findings, which will be presented simultaneously at the European Society for Medical Oncology conference in Barcelona. 

See also: Hatten Land provides update on judicial management application; appoints joint judicial managers

Charlotte Allerton, head of discovery and early development at Pfizer, said in an interview that the company hopes ponsegromab will enable weight gain that allows patients to tolerate more treatment and “be more active, which of course will improve their overall health”.

Pfizer is discussing development plans with regulatory agencies and aims to begin registration-enabling studies in 2025. The company is also testing ponsegromab in patients with heart failure and high levels of GDF-15. Allerton said the company is exploring other conditions linked to elevated GDF-15, such as chronic kidney disease.

TAGS
×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.